Pharma Capital
EPIC: CLIN
Market: AIM
52-week High/Low: 1,149.00p / 671.71p
Sector: Pharma & Biotech
Market Cap: 1,214.99M

Clinigen is a rapidly-growing specialty pharmaceutical and service company with a unique business model dedicated to delivering the right medicine to the right patient at the right time to improve the quality of people's lives around the world.

To achieve our aim, we have built a group of complementary businesses which can operate efficiently in a complex global regulatory environment and which can ensure that precious medicines are delivered securely and effectively, whenever they are needed throughout the production lifecycle. Through four businesses, Clinigen Clinical Trial Services, Idis Managed Access, Idis Global Access and Clinigen Specialty Pharmaceuticals, we provide patient access to our own and other pharmaceutical companies' products, whether to meet unmet medical needs or for use in clinical trials.

Clinigen is traded in the NEX Exchange HERE

Clinigen Group PLC

www.clinigen.co.uk

Interactive graph

col 3
col 4
col 5
col 6

Big picture - Why invest in Clinigen Group PLC

Clinigen Group PLC Snapshot

Clinigen’s mission is to deliver the right medicine to the right patient at the right time, to improve the quality of people’s lives around the world. There are only three ways for a patient to ethically access a medicine: through a clinical trial, licensed, or unlicensed route and we are the only company to globally manage access across all three routes.

Clinigen is unique in its ability to operate across all three stages of the drug lifecycle.

Unique Experience

  • Our combination of businesses are unique and synergistic enabling us to centrally manage access to treatments for patients across the clinical trial, licensed and unlicensed routes.
  • For 30 years, we have been trusted by industry and healthcare providers the world over to enable access to more innovative medicines, in more countries, for more patients than anyone else.

ETHICAL SERVICE DELIVERY

We are the leading global patient access specialist working to provide ethical and compliant access to unlicensed and licensed medicines for healthcare providers and their patients with unmet medical need.
All of our services are backed by a team of over 500 dedicated internal subject matter experts, with unsurpassed local market knowledge and global regulatory expertise to ensure ethical and compliant delivery of medicines.

THOUGHT LEADERSHIP

We have pioneered many of the access service offerings commonly used in the industry today and continue to innovate to help patients in need around the world.

SPECIALIST FOCUS

Our sole focus is to enable patient access to medicines in a fully compliant, ethical and efficient manner. We are built to help you meet the evolving demands of global access across the entire product lifecycle. 

GLOBAL REACH

Our global footprint extends to supplying 113 countries worldwide and our regulatory expertise and local market knowledge can address patient access needs anywhere in the world.

Clinigen Clinical Trial Services (CTS):

We use our global expertise, systems and relationships to source and manage the supply of commercial medicines to pharmaceutical companies for use exclusively in clinical trials. This requires excellent knowledge of the global pharmaceutical market, the regulatory processes and customs authorities of countries all over the world, along with a high tech supply chain with guaranteed quality and safety standards that can deliver swiftly.

Find out more about Clinigen Clinical Trial Services.

Idis Managed Access (MA):

On behalf of pharmaceutical and biotech companies, we manage essential programs that provide access to critical pre-approval medicines for physicians and their patients all over the world. But what is a managed access program? Known by many terms from ‘expanded access’ and ‘named patient’ to ‘compassionate use’ and ‘early access’, a managed access program enables physicians to access treatments that are not available in their own country for patients with an unmet medical need. Wherever they are, we can deliver treatments quickly, efficiently and, most importantly, ethically.

Find out more about Idis Managed Access.

Idis Global Access (GA):

Idis Global Access (GA) is the global leader in providing ethical, compliant access to unlicensed or unavailable medicines, meeting the demands of pharmacists and physicians around the world treating patients with unmet medical need.

For pharmacists and physicians, we provide a ‘go-to’ solution to assist them in accessing medicines for their patients who have no other treatment options available.

For pharmaceutical companies, we provide solutions to assist them in extending the reach of their products into regions where unmet patient need exists. This could be due to delays in commercial access, a planned lack of commercial presence, product supply shortages or market discontinuations.

Find out more about Idis Global Access.

Clinigen Specialty Pharmaceuticals (SP):

We acquire niche medicines that don’t fit into the portfolios of other pharmaceutical companies. These are typically hospital-only treatments for rare or life-threatening diseases. We specialise in revitalising and ensure that products will continue to be marketed and distributed responsibly once they have joined the Clinigen portfolio. All the while, we’re ensuring that patients already using the medicine continue to get the treatment they need, while the company whose product we have acquired can feel confident that its reputation is in safe hands.

Find out more about Clinigen Specialty Pharmaceuticals.

Link Healthcare:

We provide local and regional commercial access to vitally important specialist pharmaceutical and medical technology products focused in the regions of Asia, Africa and Australasia.

Find out more about Link Healthcare.

We are currently 500+ people, headquartered in Burton-on-Trent in the UK, with offices in London, Weybridge, Surrey, the US, Australia, China, Japan, South Africa and Singapore. With a customer services team who speak over 19 languages between them, our clients from all over the world find us easy to do business with, while physicians and pharmacists find us a valuable source of information about how to access the medicines they need for their patients.

Shaun Chilton
Chief Executive Officer

Shaun holds responsibility for the Group achieving its key performance indicators on a day to day basis and plays a central role in setting and executing the Group strategy.

He previously held the position of President within KnowledgePoint360 Group, a global pharmaceutical information and services operation. Shaun has 20 years’ experience in the industry across a range of disciplines, including commercial, strategic, operational and sales and marketing roles for companies such as Pfizer and Sanofi.

Shaun become CEO in November 2016.

 

Martin Abell
Chief Financial Officer

Before joining Clinigen, Martin worked at the FTSE 250 recruitment group Hays plc.

At Hays, Martin spent the first part of his career as Head of Investor Relations and M&A, and was later appointed Finance Director for the Continental Europe and Rest of World division which operated across 21 countries with revenues of over £1bn.

Previously, Martin held several financial roles at the FTSE 100 logistics group, Exel plc (now part of Deutsche Post) including Financial Controller of two of the UK divisions. He is a qualified Chartered Accountant, having trained at PwC in the M&A Transaction Services team.

 

Steve Glass
Chief Commercial Officer

Steve has 25 years’ experience in the international pharmaceutical and biotech industry.

During this time he has held a variety of senior international commercial operations and business development roles, including most recently CEO and founder of Orbona Pharma Ltd. He joined us from Orbona in 2014, bringing insight, experience and a successful track record of product development to the team. In 2016, Steve became Chief Commercial Officer.

 

Ivo Timmermans
Chief Medical Officer

Ivo Timmermans joined Clinigen Group in February 2016 as Chief Medical Officer, with global responsibility for regulatory issues, pharmacovigilance, medical affairs and product information.

Ivo has over twenty years of experience in the pharmaceutical industry. He has worked for Wellcome, GlaxoWellcome, BASF Pharma, Rhein Biotech and was in recent years an independent consultant. His previous roles have included positions as global medical director, global strategic advisor and CEO of start-up companies. Ivo graduated as Medical Doctor from the University of Nijmegen (Netherlands) and holds an MBA degree from Henley Management College (Henley-on-Thames, UK).

 

Debra Ainge
Chief Operating Officer

As Chief Operating Officer of Clinigen, Debra oversees the key functions that underpin the Group's central operating platform.

Debra joined Clinigen in 2011 as Head of Project Management in Clinigen Managed Access and has held various roles since then, most recently Director of Corporate Projects where she oversaw the acquisitions and integration of Idis and Link Healthcare. Before joining Clinigen she worked in a variety of research and development roles within AstraZeneca. She has 20 years’ experience in the pharmaceutical sector in both large and small/mid-size organisations including R&D, Speciality and Service Pharma. Debra holds a degree and PhD from Newcastle University, and completed post-doctoral studies at the University of Lausanne.

 

Johann Willemse
Chief Commercial Officer

 

Jessica Archer
Global Human Resources Director

Jessica has nine years’ experience in Human Resources. She joined Clinigen in 2014 as HR Business Partner and became the Global HR Director in 2016.
Prior to Clinigen, Jessica was HR Manager at Mondelez International (formerly Kraft/Cadbury). She has also worked as an HR Advisor and in Operations Management at Barclays and started her HR career at Sainsbury’s.

A member of the Chartered Institute of Personnel and Development, Jessica has a CIPD Advanced Diploma in HR Management from the University of Manchester and obtained NVQ level 4 in Operations Management during her time at Barclays.

The following were the significant shareholders as at 3 May 2017.

Shareholder
Number of shares held
% issued share capital
AXA Framlington Investment Managers
6,869,102
5.97%
Rathbones
6,275,531
5.45%
Old Mutual Global Investors
5,770,085
5.01%

Wasatch Advisors 

4,996,185
4.34%
Octopus Investments
4,605,991
4.00%
Andrew Leaver
4,538,506 
3.94%
BAE Systems Pensions
4,124,466
3.58%
Henderson Global Investors
4,091,399
3.55%

Neuberger Berman

4,070,688
3.54%

 

General enquiries 
Tel:+44 (0) 1283 495 010

Product enquiries
Tel: +44 (0) 1283 494 340

 

HEAD OFFICE

Clinigen, Pitcairn House, Crown Square, First Avenue, Burton-on-Trent, Staffordshire, DE14 2WW

Tel:+44 (0) 1283 495 010

[email protected]

 

EUROPEAN OFFICE

Clinigen CTS, Pitcairn House, Crown Square, First Avenue, Burton-on-Trent, Staffordshire, DE14 2WW

Tel: +44 (0) 1283 495 010

Fax: +44 (0) 1283 495 011

 

US OFFICE

Clinigen CTS Inc., Three Crescent Drive, Suite 110, Navy Yard Corporate Center, Philadelphia, PA 19112

Tel: +1 (215) 558 7001

Fax: +1 (215) 336 0705

Nominated Advisor
Michael Meade
Numis Securities Limited

The London Stock Exchange Building
10 Paternoster Square
London
EC4M 7LT
Tel: +44 (0) 20 7260 1000

Joint Broker
James Black
Numis Securities Limited

The London Stock Exchange Building
10 Paternoster Square
London
EC4M 7LT
Tel: +44 (0) 20 7260 1000

Joint broker
Marcus Jackson
RBC Capital Markets
Thames Court
One Queenhithe
London
EC4V 3DQ
Tel: +44 (0) 20 7653 4000

Legal Advisor
Addleshaw Goddard LLP

Milton Gate
60 Chiswell Street
London
EC1Y 4AG

Auditors
PriceWaterhouseCoopers LLP

Cornwall Court
19 Cornwall Street
Birmingham
B3 2DT

Registrar
Equiniti Limited

Aspect House
Spencer Road
Lancing
West Sussex
BN99 6DA

Media relations
Melanie Toyne-Sewell
Instinctif Partners Limited

65 Gresham Street
London
EC2V 7NQ
Tel: +44 (0) 20 7457 2020
Email: [email protected]

Clinigen Group PLC Timeline

View All

Market Reports Including CLIN

VIEW ALL

Executive video interviews

VIEW ALL VIDEOS

© biotech Capital 2017

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.